FOLH1 and metastatic prostate carcinoma: Further in vivo antitumor activity studies in heterotopic, orthotopic, and metastatic prostate cancer models in mice showed that PSMA-targeted prodrug strategy selectively and effectively inhibited PSMA-expressing tumor growth and prolonged animal survival with no obvious toxicity.